The therapeutic application of Солантра (Ivermectin 1% cream) is applied in addressing the signs and symptoms of a specific, chronic inflammatory skin condition, and may be part of symptomatic management that supports long-term stability. The cream is commonly used to help with the inflammatory lesions of rosacea in adult patients.

Managing Inflammatory Lesions of Rosacea

This topical preparation is commonly used to help manage symptoms related to inflammatory or irritative states on the face, specifically the papules (red bumps) and pustules (pimples) that characterize moderate-to-severe papulopustular rosacea. The clinical benefit generally includes a reduction in the lesion count, which helps to ease the physical discomfort that may be part of this chronic condition, and contributes to improved day-to-day comfort during symptomatic periods. The treatment generally contributes to easing the overall symptom load in situations where patients experience these signs of inflammation.

Sustaining Skin Clearing and Symptom Control

Using Солантра is considered relevant for managing symptoms that interfere with daily comfort. This therapeutic approach assists with maintaining functional stability by promoting symptom management and supports general well-being during symptomatic phases. It is often used in settings where short-term symptom stabilization is important and applied in scenarios where additional management of discomfort is required.

---

Quick Fact: Relief for Inflammatory Rosacea Symptoms The treatment is commonly used to help with symptoms related to moderate-to-severe papules and pustules, supporting general well-being.

Regulatory References

1. National Institutes of Health (NIH) DailyMed overview

Eligibility Map: Who Can and Cannot Use Солантра? — Official Regulatory Information

Eligibility Scope

Population Status	Regulatory Classification	Details (as stated in label)
Approved Population	Allowed	Adult patients (18 years of age and older). Geriatric patients (65+) are permitted; no dosage adjustment is necessary.
Absolute Contraindication	Contraindicated	Patients with known hypersensitivity (allergy) to the active substance, ivermectin, or to any of the product's excipients.
Pediatric Use	Not Recommended	Use in children and adolescents under 18 years is not recommended; safety and efficacy have not been established.
Pregnancy Status	Not Recommended	The medicine is not recommended during pregnancy (EMA). FDA advises use only if the potential benefit justifies the potential risk to the fetus.
Lactation Status	Discontinuation Required	A decision must be made whether to discontinue breast-feeding or to discontinue therapy (EMA/FDA).

Condition-Specific Eligibility Rules

• Severe Hepatic Impairment: Caution should be exercised in treating these patients, as the product has not been studied in this population.
• Renal Impairment: Caution should be used as the product has not been studied in patients with kidney problems.

Connection to the Overall Eligibility Profile

The official eligibility profile is strictly defined by regulatory documents, establishing that use is only approved for the adult population. The sole absolute prohibition for use is a known hypersensitivity to the drug or its inactive ingredients. Furthermore, the label advises against use in pregnancy and mandates conditional use for breastfeeding women. Use is explicitly not recommended in the pediatric population because safety and efficacy data have not been established in patients under 18 years of age.

Interactions with other medicines and products

The official interaction profile for Ivermectin 1% cream is limited due to the product's minimal systemic absorption. No formal drug-drug interaction studies have been performed for this topical formulation. Consequently, no medicinal product combinations are formally classified as contraindicated in the official regulatory labeling.

Pharmacokinetic Interaction Advisory

The primary interaction pattern documented is pharmacokinetic in nature. The active ingredient, ivermectin, is identified as a substrate of the Cytochrome P450 3A4 (CYP3A4) enzyme, which metabolizes the drug. This metabolic information forms the basis for a formal regulatory advisory:

• Caution is advised when the cream is used concomitantly with potent CYP3A4 inhibitors, as this combination may lead to a significant increase in the systemic plasma exposure of ivermectin.

Conversely, regulatory documents state that the cream itself, at therapeutic concentrations, neither inhibits nor induces major human CYP450 enzymes. Therefore, it is not expected to modify the exposure of other co-administered medicines that are metabolized by these enzymes.

Interactions with Food, Alcohol, and Supplements

No specific interaction patterns involving food, alcohol, herbal products, or supplements are formally documented in the official regulatory labeling. Furthermore, no mandatory timing separation rules are required for administration with other medicines, according to the official product information.

Ivermectin exhibits a dual mechanism defined by two distinct actions: targeted modulation of invertebrate ion channels and suppression of host inflammatory signaling.

---

Targeted Modulation of Invertebrate Ion Channels

This primary domain involves Ivermectin's action on Glutamate-Gated Chloride Channels (GluCls) present in the nerve and muscle cells of susceptible organisms, such as Demodex mites. The binding acts as a positive allosteric modulator, dramatically increasing the chloride ion influx. This rapid influx leads to cellular hyperpolarization, which functionally induces the paralysis and loss of neuromuscular control in the mite. The loss of neuromuscular control and subsequent mite elimination removes a microbial entity that acts as a potent immunological initiator.

---

️ Suppression of Local Inflammatory Signaling

The secondary mechanistic domain involves the regulation of the skin's innate immunity. Ivermectin acts as an inhibitor of the protease Kallikrein-5 (KLK5), resulting in a reduced synthesis rate of the pro-inflammatory peptide LL-37. Concurrently, it engages mechanisms that suppress the activation of the NF-κB pathway, leading to a downregulation of pro-inflammatory cytokines like IL-6 and TNF-α. This interference with key inflammatory mediators and transcription factors regulates the local signaling response. This change in pathway activity facilitates the adjustment of the local tissue environment.

Administration Guidelines for Солантра

The use of Солантра (Ivermectin 1% cream) is defined by a standardized set of protocols to ensure proper administration. The medication is designated exclusively for topical (cutaneous) application to the face.

Dosing and Frequency

Солантра is applied once daily. The amount used is precisely defined: a pea-size amount should be applied to each of the five areas of the face—the forehead, chin, nose, and each cheek. This is spread in a thin layer over the affected areas. If a daily dose is missed, the protocol involves applying the next dose at the usual scheduled time, without applying a double or extra dose to compensate.

Usage Rule	Detail
Administration Route	Topical (Cutaneous) use on the face only.
Dosing Schedule	A pea-size amount to each of the five facial areas.
Frequency Pattern	Once daily.
Course Duration	The maximum treatment course is typically up to 4 months and may be repeated; treatment should be discontinued if no improvement is noted after three months.

Administration Instructions

The standardized instructions specify that the cream application must strictly avoid contact with the eyes, lips, and mucosal surfaces. The protocol includes washing hands immediately following the application of the cream to the face. For pediatric use, the safety and efficacy of the cream have not been established in individuals under 18 years of age.

These parameters collectively define the standardized use protocol for the medication, governing the route, amount, frequency, and time-based characteristics for its application.

Research Evidence / Overview of Studies for Солантра

---

Evidence for Use in Papulopustular Rosacea

The core research for Солантра (Ivermectin 1% cream) was studied for a specific, chronic inflammatory skin condition, namely the papules and pustules (red bumps and pimples) associated with moderate-to-severe rosacea in adults. Research was conducted primarily through large, international Randomized Controlled Trials (RCTs), with studies observing responses over defined time intervals, typically 12 weeks, comparing the cream against an inactive vehicle cream (a placebo).

In these research scenarios, the studies monitored the condition using an Investigator's Global Assessment (IGA) score, which describes how symptoms are measured on a scale of severity. Research examined data show patterns related to the total number of papules and pustules. Findings describe patterns observed in the studies where a specific portion of the observed populations achieved a low IGA score of "clear" or "almost clear" at the Week 12 endpoint. Patient-reported outcomes (PROs) were used to gather evidence describing how patients reported their experience, capturing outcomes related to physical discomfort.

Comparative Study Landscape

Beyond the comparison against an inactive cream, research has also examined Солантра alongside other established topical treatments used for this condition. Studies explored the use of Ivermectin 1% cream compared with other standard options, such as metronidazole 0.75% cream, in active-controlled randomized trials. Studies comparing the cream to another established topical treatment reported changes in the count of inflammatory lesions across the groups over the comparison period, contributing to the broader evidence landscape.

---

Long-Term Follow-up and Sustained Observation

The use of Солантра was evaluated in extension studies that followed some patients for a total of up to 52 weeks of continuous observation. Research examined what data show patterns related to sustained outcomes throughout these extended periods. Studies monitored outcomes describing episodic or acute changes after treatment discontinuation. Evidence derived from these settings indicates that, given the chronic nature of the condition, symptoms may return over time after the cessation of use. Long-term effects are not fully established beyond the observation period of these one-year extension studies, and research continues to explore these long-term patterns.

---

Research in Specific Adult Populations

The clinical trials were primarily conducted in a broad group of adults aged 18 and older. Specific analysis was conducted for the cream was observed in older adults (aged 65 and over), with research describing patterns in this population compared to younger subjects. Results apply only to the populations studied, which were subjects with moderate-to-severe disease.

---

Understanding Evidence Gaps and Remaining Uncertainty

Evidence contributes to the broader evidence landscape for the primary indication, but certain areas are still emerging. Data for certain groups remain insufficient, particularly for individuals presenting with the mild severity subtype of rosacea or for those with subtypes that are not characterized by papules and pustules. Comparative evidence is lacking for specific newer treatments. Additionally, the majority of the patients enrolled in the main international trials were noted to be from a single ethnic background (Caucasian/White). Therefore, subgroup findings are uncertain when applying the research to populations with different demographic profiles. Research does not determine whether an individual will observe similar patterns; findings describe group patterns, not personal outcomes.

Key Studies & References

1. Ivermectin topical cream 1% - NIH DailyMed Drug Label Information

Common questions about Солантра (FAQ)

Q: Is Солантра considered a long-term treatment option?

A: Rosacea is a chronic condition, and the official instructions indicate that the treatment course may be repeated if necessary. Clinical studies have evaluated the safety and effectiveness of the cream during continuous observation periods extending up to 52 weeks.

Q: What are the signs of a serious allergic reaction to Солантра?

A: Serious adverse reactions are listed in patient information materials. Signs of a severe allergic or hypersensitivity reaction may include the development of hives, shortness of breath, or swelling of the face, lips, tongue, or throat.

Q: How long does it typically take for patients to see an improvement with Солантра?

A: According to clinical trial data, some patients may observe the onset of treatment effect as early as the second week of use. Consistent improvement is then typically seen over the full 12-week study period, which is the main time frame used to assess effectiveness.

Q: What kind of changes should I generally expect during the first few weeks of using Солантра?

A: Official warnings and precautions state that a temporary worsening of rosacea symptoms, described as a transient aggravation, may occur when treatment is first started. This temporary reaction usually resolves naturally within the first week of continued use.

Q: Is it normal to see results quickly or should I expect a slow onset of benefits?

A: Improvement in inflammatory lesions may be noted after several applications. However, based on the studies, the benefits are often seen gradually, with continuous positive changes observed over the entire treatment period.

Q: Does Солантра interact with common over-the-counter topical treatments?

A: Formal drug interaction studies involving the cream and other topical treatments have not been specifically performed. However, official administration guidelines indicate that cosmetics or other non-medicinal products may be applied to the skin after the cream has fully dried.

Q: Is it true that the active ingredient in Солантра is also used as an anti-parasitic for other conditions?

A: Yes, the active ingredient is ivermectin, which is categorized as an antiparasitic agent. While Солантра cream is used topically for rosacea, ivermectin is also approved in different formulations for treating other parasitic conditions, such as certain infections or head lice.

Q: Does Солантра cure the underlying skin condition, or just manage symptoms?

A: Rosacea is defined as a chronic (long-lasting) skin condition. The product is intended as a treatment to reduce the inflammatory lesions and manage the symptoms, and the treatment course may need to be repeated over time.

Q: Is the concentration of the active ingredient in Солантра the same across all official forms?

A: The product, as a topical cream, is approved with a single concentration of 1% ivermectin. It is important to note that this specific product only comes in this one strength and form.

Q: Which regulatory bodies have approved Солантра?

A: Marketing authorisation for the cream has been granted by major international government health authorities. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Does Солантра contain any steroids?

A: Official documents confirm that the product contains the active ingredient ivermectin, which is part of the macrocyclic lactone class. The cream does not contain any corticosteroids (steroids).

Q: Are there any known long-term safety concerns associated with using Солантра?

A: Official safety data from clinical studies indicate that no specific long-term safety issues have been identified. However, regulatory experience and data regarding continuous use for periods extending beyond one year remain limited.

Q: Are there any cosmetic products or moisturizers that should not be used alongside Солантра?

A: Official guidelines state that cosmetic products, including moisturizers, may be applied to the treated area. The instruction is to wait until the medicinal product has completely dried before applying these other items.

Q: Is it safe to use makeup or sunscreen while being treated with Солантра?

A: Yes, the official administration instructions permit the use of cosmetics, which covers both makeup and sunscreen. The guidelines recommend waiting until the cream has fully dried before applying these products to the skin.

Q: Does the manufacturer recommend a specific waiting period before applying other products to the skin?

A: The official guidelines recommend a conditional waiting period for other topical products, including cosmetics. These items may be applied to the skin once the medicinal product has completely dried.

Q: Are there different usage considerations for men and women when using Солантра?

A: Official prescribing information indicates that the administration and dosage instructions are the same for all adult patients, regardless of sex. Clinical studies included both male and female adult subjects.

Storage and Handling of Soolantra (Ivermectin) Cream

Soolantra cream must be stored at Controlled Room Temperature, which is between 20°C to 25°C (68°F to 77°F). The official labeling permits brief temperature excursions from 15 C to 30 C. It is mandatory to protect the cream from freezing to maintain its stability.

Container and Child Safety

After each use, the tube must be kept tightly closed. For safety, the cream must be stored out of the sight and reach of children at all times.

Disposal Requirements

Unused or expired Soolantra should be disposed of according to official guidelines, preferably through a drug take-back program. If a take-back option is unavailable, the cream should be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash. The cream must not be flushed down the toilet or poured into a sink.